Impact of pharmacodynamic biomarkers in immuno-oncology (IO) phase 1 clinical trials.

被引：3
|
作者：
Salawu, Abdulazeez
Chen, Rachel
Hernando-Calvo, Alberto
Araujo, Daniel Vilarim
Bernal, Marc Oliva
Liu, Zhihui
Siu, Lillian L.
机构：
[1] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Princeton Univ, Princeton, NJ 08544 USA
[3] Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Inst Catala Invest Biomed Bellvitge IDIBELL, Inst Catala Oncol Hospitalet, Barcelona, Spain
[5] Univ Hlth Network, Dept Biostat, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.2653
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2653
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials
    Salawu, Abdulazeez
    Hernando-Calvo, Alberto
    Chen, Rachel Y.
    Araujo, Daniel, V
    Oliva, Marc
    Liu, Zhihui A.
    Siu, Lillian L.
    [J]. EUROPEAN JOURNAL OF CANCER, 2022, 173 : 167 - 177
  • [2] A risk stratification model for toxicities in phase 1 immuno-oncology (P1-IO) trials.
    Hernando-Calvo, Alberto
    Salawu, Abdulazeez
    Bernal, Marc Oliva
    Araujo, Daniel Vilarim
    Liu, Zhihui
    Chen, Rachel
    Siu, Lillian L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Pharmacodynamic biomarkers for first in class early phase immuno-oncology trials; opportunities and challenges
    Katugampola, S.
    Spicer, J.
    Karagianis, S.
    Joseph, D.
    Bax, H.
    Pellizzari, G.
    Gillett, C.
    Woodman, N.
    Ottensmeier, C.
    King, E.
    Jones, T.
    Thomas, G.
    Chudley, L.
    Joseph-Pietras, D.
    Mellor, S.
    Dobbs, N.
    Barton, C.
    Acton, G.
    McGuigan, L.
    Jones, P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 55 : S27 - S27
  • [4] The landscape of immuno-oncology clinical trials in China
    Wu, D.
    Huang, H.
    Li, N.
    Wang, S.
    Fang, H.
    Yu, Y.
    Bai, Y.
    Xu, B.
    Sun, Y.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [5] Immuno-Oncology in Cancer Care is a Fantastic Opportunity for Interventional Oncology: IO4IO (Interventional Oncology for Immuno-Oncology) Initiative
    Thierry de Baère
    Lambros Tselikas
    Frederic Deschamps
    Jean Charles Soria
    Aurélien Marabelle
    [J]. CardioVascular and Interventional Radiology, 2018, 41 : 825 - 827
  • [6] Immuno-Oncology in Cancer Care is a Fantastic Opportunity for Interventional Oncology: IO4IO (Interventional Oncology for Immuno-Oncology) Initiative
    de Baere, Thierry
    Tselikas, Lambros
    Deschamps, Frederic
    Soria, Jean Charles
    Marabelle, Aurelien
    [J]. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2018, 41 (06) : 825 - 827
  • [7] Precision immuno-oncology (IO) ISH/IF multiplex panel: Spatial detection of cytokines and IO biomarkers
    Patel, Bhavika
    Dennison, Brenna
    Allen, Stephanie
    Stapleton, Jacob
    Archuleta, Roni
    Rath, Mary Lou
    Mehra, Navi
    Talwalkar, Sameer S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Precision immuno-oncology (IO) ISH/IF multiplex panel: Spatial detection of cytokines and IO biomarkers
    Dennison, Brenna
    Allen, Stephanie
    Patel, Bhavika
    Stapleton, Jacob
    Archuleta, Roni
    Rath, Mary Lou
    Mehra, Navi
    Talwalkar, Sameer S.
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [9] Oxidative Biomarkers of Immuno-Oncology
    Ekmekcioglu, Suhendan
    [J]. TURKISH JOURNAL OF IMMUNOLOGY, 2019, 7 (03): : 132 - 136
  • [10] Impact of pharmacodynamic biomarkers in phase I immune-oncology trials
    Salawu, A. T.
    Chen, R.
    Calvo, A. Hernando
    Araujo, D. V.
    Oliva, M.
    Liu, Z.
    Siu, L. L.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S849 - S850
12345